Latest news with #JohnDwyer
Yahoo
21-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
Yahoo
20-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
Yahoo
20-05-2025
- Health
- Yahoo
Global Alzheimer's Platform Foundation Applauds FDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimer's Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer's disease. Fujirebio's Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer's—a critical element in accurately diagnosing Alzheimer's disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF). GAP is proud that its AD biomarker study, Bio-Hermes-001, played a principal role in the dataset used to support Fujirebio's FDA application for clearance of the first groundbreaking blood based IVD available for the diagnosis of Alzheimer's Disease (AD). Bio-Hermes-001 was designed to provide head-to-head comparisons of data available on leading Alzheimer's blood tests and PET tests from 1,000 highly characterized and representative study volunteers demonstrating signs and symptoms associated with Alzheimer's disease. John Dwyer, President of the Global Alzheimer's Platform Foundation stated, 'We commend the FDA's clearance of Fujirebio's Lumipulse submission, as this IVD is poised to fundamentally change the Alzheimer's diagnostic process and significantly improve the ability of physicians to accurately access and treat AD and empower people to take action to address their condition. GAP is extremely proud that its Bio-Hermes-001 biomarker study materially contributed to this landmark IVD. We intentionally designed that unique study to drive forward new technologies and treatment processes for Alzheimer's and related dementias. We want to thank the thousand volunteers who participated in Bio-Hermes 1; the numerous clinical trial sites that tirelessly worked with us on the study as well as the dozens of technology, pharmaceutical, and philanthropy partners that collaborated with us to support Bio-Hermes. GAP celebrates this remarkable clearance, which has the potential to transform the future of AD diagnostics and treatments.' About the Global Alzheimer's Platform Foundation (GAP)The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible. Contact: media@
Irish Independent
14-05-2025
- General
- Irish Independent
People living in Wexford buildings without emergency exits could be in grave danger – ‘God forbid if there was a fire there'
The lack of emergency exits on a New Ross block of buildings containing 'a village of Romanians' could result in 'serious consequences' unless a fire inspection is carried out on the premises according to Cllr John Dwyer.
Yahoo
11-03-2025
- General
- Yahoo
Illinois Fire Service Institute offering active shooter course in Champaign
CHAMPAIGN, Ill. (WCIA) — The Illinois Fire Service Institute (IFSI) has scheduled an active shooter course in Champaign for this May. IFSI is holding an Active Shooter Incident Management (ASIM) course from May 6-8 at the First Christian Church at 3601 S Staley Road. This advanced course is a 24-hour performance-level class designed to improve incident management and integration of law enforcement, fire and EMS responders to active shooter events. Champaign community invited to enjoy coffee with a cop 'The course provides a model framework for use by law enforcement, fire and EMS command staff to manage active shooter event response to improve time to threat neutralization, medical intervention and survivability of victims,' an ASIM flyer reads. This course is being hosted by the Champaign County Emergency Management Agency. ASIM is also providing the statistical profile of a typical Active Shooter Event (ASE), which includes: A model ASE integrated response process The Active Shooter Incident Management Checklist(TM) Organizational building blocks for an integrated response including: Contact Team Rescue Task Force Tactical Perimeter Triage Transport Intelligence Reunification Progressively challenging full length ASE functional exercise scenarios Hands-on experience in multiple response roles Introduction to Complex Coordinated Attacks (CCA) Experience applying and working with the NIMS Incident Command System Improvised Explosive Device and Static/Barricade scenarios CCA Case Studies and capstone exercise scenario The City of Champaign wants your input on downtown improvements The ASIM course provides participants, and enrollment is limited to command and supervisory level personnel, including: 30 Law Enforcement 20 Fire/EMS personnel Five Emergency Communicators (dispatchers) Two Public Information Officers (PIOs) Two Emergency Managers One Helicopter Pilot The course is provided by grant funded training, meaning there is no cost to student or agency. The registration deadline is March 21, and the registration pin (case sensitive) is FY25CHMAY. The two ways to register are by visiting the c3pathways website or by scanning the QR code on the flyer. The local point of contact is John Dwyer, who can be reached at 217-384-3826 or jdwyer@ For more information on the course, contact David Saitta, NIMS/ICS Program Manager, at 217-333-6952 or dsaitta@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
